UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019277
Receipt number R000021645
Scientific Title Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide
Date of disclosure of the study information 2015/10/08
Last modified on 2015/10/08 15:23:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide

Acronym

Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide

Scientific Title

Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide

Scientific Title:Acronym

Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To find novel biomarkers for predicting the efficacy of Enzalutamide usung biopsy specimens of castration resistant prostate cancer patients.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To analyze gene mutation or expression profiles in the local or metastatic biopsy specimens of castration resistant prostate cancer patients.
To find novel biomarkers to ecaluate the gene mutation or expression in blood or urine sampls.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Gene

Interventions/Control_1

Prostate biopsy before Enzalutamide treatement for CRPC

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Castration resistant prostate cancer patients who are going to receive Enzalutamide treatment are included in this study.
Local recurrent cancer is detected by MRI.

Key exclusion criteria

Patients who are unable to receive prostate biopsy safely.
Pathents with severe side effect by previous prostate biopsy.
Allergy to Enzalutamide.
Refuse the study.
Age is younger than 20 years old.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Osamu Ogawa

Organization

Kyoto University Graduate School of Medicine

Division name

Urology

Zip code


Address

54 Shogoinkawahara-cho, Sakyo-ku, Kyoto

TEL

075-751-3325

Email

ogawao@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naoki Terada

Organization

Kyoto University Graduate School of Medicine

Division name

Urology

Zip code


Address

54 Shogoinkawahara-cho, Sakyo-ku, Kyoto

TEL

075-751-3337

Homepage URL


Email

nterada@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Kyoto University

Institute

Department

Personal name



Funding Source

Organization

Astellas Pharma Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 10 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2015 Year 09 Month 29 Day

Date of IRB


Anticipated trial start date

2015 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 10 Month 08 Day

Last modified on

2015 Year 10 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021645


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name